Leukemia Clinical Trials in Texas

Showing 481-500 of 1,290 trials

AVID100 in Advanced Epithelial Carcinomas

NCT03094169

Approximately 90 male and female patients with documented solid tumor malignancies of epithelial origin that are locally advanced or metastatic, and either refractory to standard therapy or for whom no standard therapy is available, will be entered into this Phase 1a/2a, multicenter, open-label, dose-escalation, cohort study of AVID100. Phase 2a will include evaluation of patient with EGFR-overexpressing squamous histology non-small cell lung cancer, squamous cell carcinoma of the head and neck, and triple negative breast cancer

Solid Tumor, AdultTriple Negative Breast CancerHead and Neck Squamous Cell Carcinoma+1 more

Formation Biologics49 participantsStarted Feb 2017

New Haven, Connecticut, United States • Grand Rapids, Michigan, United States • New York, New York, United States +7 more locations

COMPLETEDPhase 355 miles

Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children

NCT03859700

Open-label, follow-up study for subjects who completed the EPITOPE study.

Peanut Allergy

DBV Technologies304 participantsStarted Dec 2018

Tucson, Arizona, United States • Little Rock, Arkansas, United States • Los Angeles, California, United States +23 more locations

PreviousPage 25 of 65Next

AVID100 in Advanced Epithelial Carcinomas

Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children

Leukemia Trials in Other Cities

A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation

APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

MAGIC Ruxolitinib for aGVHD

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

A Registry for People With T-cell Lymphoma

Non-Guided vs. Guided Surgery to Immediately Loaded PrimeTaper Implants in Partially Edentulous Patients

A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML

Medical Access Program for Patritumab Deruxtecan

MEOI and HRQoL in CLL Patients Treated With BTKis

A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC

Other Conditions in Texas